Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives $11.75 Average Target Price from Analysts

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) has received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $11.75.

Several brokerages have recently weighed in on EVAX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a research note on Friday, January 9th. Maxim Group assumed coverage on shares of Evaxion A/S in a research note on Thursday, February 19th. They issued a “buy” rating and a $10.00 price target on the stock.

Institutional Trading of Evaxion A/S

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Evaxion A/S during the 4th quarter worth about $38,000. Wesbanco Bank Inc. acquired a new stake in Evaxion A/S in the 4th quarter worth about $48,000. Finally, SmartHarvest Portfolios LLC purchased a new stake in Evaxion A/S during the 4th quarter worth approximately $72,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion A/S Price Performance

Shares of Evaxion A/S stock opened at $3.22 on Friday. The firm has a market cap of $26.85 million, a PE ratio of -2.44 and a beta of 0.28. Evaxion A/S has a twelve month low of $1.20 and a twelve month high of $12.15. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.41. The business has a 50-day moving average price of $3.90 and a 200 day moving average price of $4.63.

Evaxion A/S (NASDAQ:EVAX) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.30 earnings per share (EPS) for the quarter. Sell-side analysts predict that Evaxion A/S will post -0.15 earnings per share for the current fiscal year.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.